ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23%
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ESSA Pharma Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Free Cash Flow
-$22.7m
CAGR 3-Years
4%
CAGR 5-Years
-13%
CAGR 10-Years
-27%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Free Cash Flow
-CA$7m
CAGR 3-Years
-190%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Free Cash Flow
-$4.5m
CAGR 3-Years
33%
CAGR 5-Years
-22%
CAGR 10-Years
5%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Free Cash Flow
$28.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Free Cash Flow
CA$639.2k
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
-15%
Spectral Medical Inc
TSX:EDT
Free Cash Flow
-CA$8.4m
CAGR 3-Years
1%
CAGR 5-Years
-38%
CAGR 10-Years
3%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Free Cash Flow?
Free Cash Flow
-22.7m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Free Cash Flow amounts to -22.7m USD.

What is ESSA Pharma Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-27%

Over the last year, the Free Cash Flow growth was -15%. The average annual Free Cash Flow growth rates for ESSA Pharma Inc have been 4% over the past three years , -13% over the past five years , and -27% over the past ten years .

Back to Top